OKYO Pharma Announces A New Agreement With Tufts Medical Center To Conduct A 40-Patient Open-Label Trial Evaluating The Efficacy, Safety Of OK-101 In Patients With Neuropathic Corneal Pain; The Investigational New Drug Is Planned To Be Filed In Q4 Of 2023
Portfolio Pulse from Benzinga Newsdesk
OKYO Pharma has announced a new agreement with Tufts Medical Center to conduct a 40-patient open-label trial evaluating the efficacy and safety of OK-101 in patients with neuropathic corneal pain. The investigational new drug is planned to be filed in Q4 of 2023.
July 28, 2023 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
OKYO Pharma's new partnership with Tufts Medical Center for a clinical trial of OK-101 could potentially boost the company's profile if the trial results are positive.
The announcement of a new clinical trial is typically seen as a positive development for a biotech company, as it indicates progress in the company's pipeline. If the trial results are positive, it could potentially lead to increased investor interest in OKYO Pharma, which could drive the stock price up in the short term.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100